71 related articles for article (PubMed ID: 22064107)
41. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
42. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
43. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
[TBL] [Abstract][Full Text] [Related]
44. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
45. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET.
Tsuchida T; Takeuchi H; Okazawa H; Tsujikawa T; Fujibayashi Y
Nucl Med Biol; 2008 Feb; 35(2):171-6. PubMed ID: 18312826
[TBL] [Abstract][Full Text] [Related]
46. Imaging infection and inflammation in children with (18)F-FDG PET and (18)F-FDG PET/CT.
Servaes S
J Nucl Med Technol; 2011 Sep; 39(3):179-82. PubMed ID: 21795366
[TBL] [Abstract][Full Text] [Related]
47. F-18 FDG PET/CT in the diagnosis of fever of unknown origin.
Balink H; Collins J; Bruyn GA; Gemmel F
Clin Nucl Med; 2009 Dec; 34(12):862-8. PubMed ID: 20139818
[TBL] [Abstract][Full Text] [Related]
48. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
[TBL] [Abstract][Full Text] [Related]
49. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
Sørensen M; Horsman MR; Cumming P; Munk OL; Keiding S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):854-61. PubMed ID: 15936570
[TBL] [Abstract][Full Text] [Related]
50. Striking lack of visualization of striatum on
López-Mora DA; Camacho V; Fernández A; Granell E; Carrió I
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):511-512. PubMed ID: 29242959
[No Abstract] [Full Text] [Related]
51. The use of PET scan in glioblastoma multiforme.
Alexiou GA; Tsiouris S; Kyritsis AP; Polyzoidis KS; Fotopoulos AD
J Neurooncol; 2008 Feb; 86(3):359-60. PubMed ID: 17634740
[No Abstract] [Full Text] [Related]
52. Bromodomain and extraterminal protein-targeted probe enables tumour visualisation
Dickmann CGF; McDonald AF; Huynh N; Rigopoulos A; Liu Z; Guo N; Osellame LD; Gorman MA; Parker MW; Gan HK; Scott AM; Ackermann U; Burvenich IJG; White JM
Chem Commun (Camb); 2023 Mar; 59(21):3126-3129. PubMed ID: 36809538
[TBL] [Abstract][Full Text] [Related]
53. Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.
Leimgruber A; Hickson K; Lee ST; Gan HK; Cher LM; Sachinidis JI; O'Keefe GJ; Scott AM
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1476-1485. PubMed ID: 32025750
[TBL] [Abstract][Full Text] [Related]
54. Lack of concordance between the F-18 fluoromisonidazole PET and the F-18 FDG PET in human glioblastoma.
De Clermont H; Huchet A; Lamare F; Rivière A; Fernandez P
Clin Nucl Med; 2011 Dec; 36(12):e194-5. PubMed ID: 22064107
[No Abstract] [Full Text] [Related]
55. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of
Okamoto M; Yamaguchi S; Sawaya R; Echizenya S; Ishi Y; Kaneko S; Motegi H; Toyonaga T; Hirata K; Fujimura M
Biomed Res Int; 2024; 2024():2973407. PubMed ID: 38449509
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
57. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
58. PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics.
Haubner R
Radiother Oncol; 2010 Sep; 96(3):280-7. PubMed ID: 20724013
[TBL] [Abstract][Full Text] [Related]
59. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
